Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 5/20 | 0.39 |
| ▸ | CTSL | P07711 | 3/20 | 0.39 |
| ▸ | CTSB | P07858 | 3/20 | 0.39 |
| ▸ | CTSS | P25774 | 3/20 | 0.39 |
| ▸ | ABCB1 | P08183 | 2/20 | 0.36 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.36 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.36 |
| ▸ | REN | P00797 | 5/20 | 0.35 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.34 |
| ▸ | BACE1 | P56817 | 2/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1863456 | 0.87 | ABCB1 (0.41) | CTSKCTSLCTSBCTSSABCB1 | |
| SCHEMBL1868247 | 0.86 | CTSK (0.39) | CTSKCTSLCTSBCTSSABCB1 | |
| SCHEMBL4973214 | 0.82 | CTSS (0.40) | CTSKCTSLCTSBCTSSABCB1 | |
| SCHEMBL4973219 | 0.82 | CTSS (0.40) | CTSKCTSLCTSBCTSSABCB1 | |
| SCHEMBL1866019 | 0.82 | CTSS (0.40) | CTSKCTSLCTSBCTSSABCB1 | |
| SCHEMBL1858119 | 0.82 | CTSS (0.40) | CTSKCTSLCTSBCTSSABCB1 | |
| SCHEMBL4972692 | 0.79 | ABCB1 (0.38) | CTSKCTSLCTSBCTSSABCB1 | |
| SCHEMBL3612209 | 0.76 | SYK (0.43) | CTSKCTSLCTSBCTSSCYP3A4 | |
| SCHEMBL3612205 | 0.76 | SYK (0.43) | CTSKCTSLCTSBCTSSCYP3A4 | |
| SCHEMBL13256311 | 0.76 | SYK (0.43) | CTSKCTSLCTSBCTSSCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110105506-A1 | Diaminoalkane aspartic protease inhibitors | VITAE PHARMACEUTICALS, INC. | 2011-05-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110105506-A1 | Diaminoalkane aspartic protease inhibitors | DNPEP, PEPD, ACE | CTSK 31/4885CTSL 82/4885CTSB 64/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.